Contributors: Castellanos, Jaime [0000-0003-1596-8383]; Romero-Sánchez, Consuelo [0000-0002-6973-7639]; Delgado Tiria, Felix Giovanni [0000-0001-6685-7507]; Universidad El Bosque [Bogota]; Génétique fonctionnelle des maladies infectieuses - Functional Genetics of Infectious Diseases; Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS); The research leading to these results has received funding from the 'Integrative Biology of Emerging Infectious Disease' Labex (Laboratoire d’excellence) under Grant Agreement number ANR-10-LABX-62-IBEID (French Government’s 'Investissements d’Avenir' program), from the European Commission Seventh Framework Program [FP7/20072–013] for the DENFREE project under Grant Agreement no. 282378, and from the Prix Duquesne. F.G.D. is registered in the Ecole Doctorale BioSPC (Université Paris Diderot) and has a PhD grant from the Colombian Department of Sciences, Technology, and Innovation (COLCIENCIAS) through the doctoral scholarship program number 679.; ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010); European Project: 282378,EC:FP7:HEALTH,FP7-HEALTH-2011-single-stage,DENFREE(2012); Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris]
نبذة مختصرة : The high levels of dengue-virus (DENV) seroprevalence in areas where the Zika virus (ZIKV) is circulating and the cross-reactivity between these two viruses have raised concerns on the risk of increased ZIKV disease severity for patients with a history of previous DENV infections. To determine the role of DENV preimmunity in ZIKV infection, we analyzed the T- and B-cell responses against ZIKV in donors with or without previous DENV infection. Using peripheral blood mononuclear cells (PBMCs) from donors living in an endemic area in Colombia, we have identified, by interferon (IFN)-&gamma
enzyme-linked immunospot (ELISPOT) assay, most of the immunodominant ZIKV T-cell epitopes in the nonstructural (NS) proteins NS1, NS3, and NS5. Analyses of the T- and B-cell responses in the same donors revealed a stronger T-cell response against peptides conserved between DENV and ZIKV, with a higher level of ZIKV-neutralizing antibodies in DENV-immune donors in comparison with DENV-naï
ve donors. Strikingly, the potential for antibody-mediated enhancement of ZIKV infection was reduced in donors with sequential DENV and ZIKV infection in comparison with donors with DENV infection only. Altogether, these data suggest that individuals with DENV immunity present improved immune responses against ZIKV.
Processing Request
No Comments.